Company profile

Vivoryon Therapeutics AG (formerly Probiodrug) specializes in the research and development of therapeutic products for the treatment of Alzheimer disease. At the end of 2018, the group has a portfolio of 2 products in clinical development phase (PBD-C06 and PQ912) and a product in the preclinical development phase.

Source: Cofisem - Last Update: 02 Jul 2019
Key Executives
Chairman of the Management Board Ulrich Dauer
Member of the Management Board Michael Schaeffer
Investor Relations Ulrich Dauer
Source: Cofisem - Last Update: 02 Jul 2019
Key figures
Millenium 2018 2017 2016 2015 2014
Net sales
Income from ordinary activities
Operating income -7.698 -9.961 -13.777 -13.393 -11.267
Cost (net) of financial indebtedness -114 -112 -170
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -7.737 -8.009 -13.891 -13.505 -11.437
Net income (Group share) -7.737 -8.009 -13.891 -13.505 -11.437
Fiscal year end 12,18 12,17 12,16 12,15 12,14
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 02 Jul 2019
Shareholder information
T&W Holding A/S 8,13 %
Den Danske Forskningsfond 8,13 %
Claus Christiansen 8,13 %
IBG Group 7,26 %
Life Science Partners 5,17 %
TVM Capital Funds 4,54 %
Edmond de Rothschild Investment Partners 3,34 %
Mackenzie Financial Corporation 3,27 %
Source: Cofisem - Last Update: 09 May 2019

Address

Vivoryon Therapeutics AG

Weinbergweg 22
DE-06120 Halle, Sachsen-Anhalt
Germany
Phone number: +49 345 555 9900
Source: Cofisem - Last Update: 02 Jul 2019

Contact

Ulrich Dauer
Source: Cofisem - Last Update: 02 Jul 2019